Lilly expands its Zepbound vial offering, as Hims pulls back on semaglutide

Comments
Loading...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. A bunch of people I know (including me) have gotten sick recently. It’s a particularly intense flu season right now. Hope everyone is taking care of themselves. 

Read the rest…

Market News and Data brought to you by Benzinga APIs